at AACR advances in breast cancer conference
 

Dr. Winer gave a talk on the treatment of her2+ breast cancer and stated that he sees a day in the not too distant future when a subset of her2+ breast cancer patients will be treated without any chemotherapy ie, just with targeted therapy or ADC (trojan horse combos like TDM-1)

He predicted pertuzumab and tdm-1 would be approved within a year or two and a poster was presented by a researcher from Emory showing a cure in mice of her2+ breast cancer with a combination (trio) of tdm-1+ pertuzumab+ avastin. Not only did the tumors disappear with this treatment they did not come back in the three months they looked before they "sacrificed" them.

All the more reason not to let the FDA or insurance companies stop the use of avastin until they determine which subgroup of breast cancer patients it helps.

I can see that this trio treatment is exceedingly pricy, but if they only need to treat for a month or two (or less) and it never recurs--they need to determine the minimal treatment time to affect the "cure" it should pass muster with the bean counters.

Re: at AACR advances in breast cancer conference
 

Wonder if this combo would work for mets?

As always thanks Lani for once more posting HOPE!

Ellie

Re: at AACR advances in breast cancer conference
 

Wow, wouldn't that be nice!

Re: at AACR advances in breast cancer conference
 

I am back on Avastin...hoping and praying that it works like last time...will be interesting to see the result. Went off a year ago, after being on about a year, due to protein in my urine, which indicated irritated kidneys. I think all of me was pretty irritated. Surprised they only cared about my kidneys.

Re: at AACR advances in breast cancer conference
 

Let's keep our fingers crossed for the future when everyone only needs targeted drugs like T DM1 and Petuzamab for a short time.
Good luck with the Avastin the second time around SoCalGal. Take good care of yourself.